Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Halim, Talha Abdul ^a   Farooqi, Ammad Ahmad ^a   Zaman, Farrukh ^a  

^a RLMC   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMENTOFLAVONE; ARSENIC TRIOXIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BOSWELLIC ACID; CISPLATIN; CURCUMIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ETOPOSIDE; HESPERETIN; HISTONE DEACETYLASE INHIBITOR; MICRORNA; MONOCLONAL ANTIBODY; NOTCH RECEPTOR; OLIGONUCLEOTIDE; ONCOPROTEIN; PHENETHYL ISOTHIOCYANATE; PROTEIN E7; PROTEIN P53; PROTEOHEPARAN SULFATE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS PROTEIN; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOGENESIS; DENDRITIC CELL; GENE SILENCING; HUMAN; LANGERHANS CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PAPILLOMAVIRUS INFECTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS CELL INTERACTION; VIRUS ENTRY; WART VIRUS; WNT SIGNALING PATHWAY;

EID: 84879051170     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-61     Document Type: Review

References (186)

1. Denny L. Cervical cancer: prevention and treatment. Discov Med 2012, 14(75):125-31.
2. Sheinfeld Gorin SN, Glenn BA, Perkins RB. The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. Adv Ther 2011, 28(8):615-39. 10.1007/s12325-011-0045-x, 21818672.
3. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006, 11:2286-302. 10.2741/1971, 1472295, 16720315.
4. Fehrmann F, Laimins LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 2003, 22(33):5201-7. 10.1038/sj.onc.1206554, 12910257.
5. Thomas M, Narayan N, Pim D, Tomaić V, Massimi P, Nagasaka K, Kranjec C, Gammoh N, Banks L. Human papillomaviruses, cervical cancer and cell polarity. Oncogene 2008, 27(55):7018-30. 10.1038/onc.2008.351, 19029942.
6. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010, 10(8):550-60. 10.1038/nrc2886, 20592731.
7. Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP. Mechanisms of cell entry by human papillomaviruses: an overview. Virol J 2010, 7:11. 10.1186/1743-422X-7-11, 2823669, 20089191.
8. Letian T, Tianyu Z. Cellular receptor binding and entry of human papillomavirus. Virol J 2010, 7:2. 10.1186/1743-422X-7-2, 2820467, 20051141.
9. Surviladze Z, Dziduszko A, Ozbun MA. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog 2012, 8(2):e1002519. 10.1371/journal.ppat.1002519, 3276557, 22346752.
10. Scheffer KD, Gawlitza A, Spoden GA, Zhang XA, Lambert C, Berditchevski F, Florin L. Tetraspanin CD151 Mediates Papillomavirus Type 16 Endocytosis. J Virol 2013, 87(6):3435-46. 10.1128/JVI.02906-12, 23302890.
11. Spangle JM, Munger K. The HPV16 E6 Oncoprotein Causes Prolonged Receptor Protein Tyrosine Kinase Signaling and Enhances Internalization of Phosphorylated Receptor Species. PLoS Pathog 2013, 9(3):e1003237. 10.1371/journal.ppat.1003237, 3597533, 23516367.
12. Abban CY, Meneses PI. Usage of heparan sulfate, integrins, and FAK in HPV16 infection. Virology 2010, 403(1):1-16. 10.1016/j.virol.2010.04.007, 2883642, 20441998.
13. Tran T, Barlow B, O'Rear L, Jarvis B, Li Z, Dickeson K, Dupont W, Zutter M. Loss of the α2β1 integrin alters human papilloma virus-induced squamous carcinoma progression in vivo and in vitro. PLoS One 2011, 6(10):e26858. 10.1371/journal.pone.0026858, 3203166, 22046385.
14. Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI, Glover TW. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 1996, 5(2):187-95. 10.1093/hmg/5.2.187, 8824874.
15. Giarnieri E, Zanesi N, Bottoni A, Alderisio M, Lukic A, Vecchione A, Ziparo V, Croce CM, Mancini R. Oncosuppressor proteins of fragile sites are reduced in cervical cancer. Cancer Lett 2010, 289(1):40-5. 10.1016/j.canlet.2009.07.017, 2987609, 19700237.
16. Moody CA, Laimins LA. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog 2009, 5(10):e1000605. 10.1371/journal.ppat.1000605, 2745661, 19798429.
17. Hsu YL, Chia CC, Chen PJ, Huang SE, Huang SC, Kuo PL. Shallot and licorice constituent isoliquiritigenin arrests cell cycle progression and induces apoptosis through the induction of ATM/p53 and initiation of the mitochondrial system in human cervical carcinoma HeLa cells. Mol Nutr Food Res 2009, 53(7):826-35. 10.1002/mnfr.200800288, 19536869.
18. Craigo J, Callahan M, Huang RC, DeLucia AL. Inhibition of human papillomavirus type 16 gene expression by nordihydroguaiaretic acid plant lignan derivatives. Antiviral Res 2000, 47(1):19-28. 10.1016/S0166-3542(00)00089-9, 10930643.
19. Wetherill LF, Holmes KK, Verow M, Müller M, Howell G, Harris M, Fishwick C, Stonehouse N, Foster R, Blair GE, Griffin S, Macdonald A. High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. J Virol 2012, 86(9):5341-51. 10.1128/JVI.06243-11, 3347351, 22357280.
20. Belleudi F, Leone L, Purpura V, Cannella F, Scrofani C, Torrisi MR. HPV16 E5 affects the KGFR/FGFR2b-mediated epithelial growth through alteration of the receptor expression, signaling and endocytic traffic. Oncogene 2011, 30(50):4963-76. 10.1038/onc.2011.203, 21625213.
21. Muto V, Stellacci E, Lamberti AG, Perrotti E, Carrabba A, Matera G, Sgarbanti M, Battistini A, Liberto MC, Focà A. Human papillomavirus type 16 E5 protein induces expression of beta interferon through interferon regulatory factor 1 in human keratinocytes. J Virol 2011, 85(10):5070-80. 10.1128/JVI.02114-10, 3126211, 21389130.
22. Surviladze Z, Sterk RT, Deharo SA, Ozbun MA. Cellular Entry of Human Papillomavirus Type 16 Involves Activation of the Phosphatidylinositol 3-Kinase/Akt/mTOR Pathway and Inhibition of Autophagy. J Virol 2013, 87(5):2508-17. 10.1128/JVI.02319-12, 23255786.
23. Cardeal LB, Boccardo E, Termini L, Rabachini T, Andreoli MA, di Loreto C, Longatto Filho A, Villa LL, Maria-Engler SS. HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. PLoS One 2012, 7(3):e33585. 10.1371/journal.pone.0033585, 3306414, 22438955.
24. Fera D, Marmorstein R. Different regions of the HPV-E7 and Ad-E1A viral oncoproteins bind competitively but through distinct mechanisms to the CH1 transactivation domain of p300. Biochemistry 2012, 51(47):9524-34. 10.1021/bi3011863, 23121466.
25. Todorovic B, Hung K, Massimi P, Avvakumov N, Dick FA, Shaw GS, Banks L, Mymryk JS. Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor. J Virol 2012, 86(24):13313-23. 10.1128/JVI.01637-12, 3503127, 23015707.
26. Schneider MA, Scheffer KD, Bund T, Boukhallouk F, Lambert C, Cotarelo C, Pflugfelder GO, Florin L, Spoden GA. The Transcription Factors TBX2 and TBX3 interact with HPV16 L2 and repress the Long Control Region of Human Papillomaviruses. J Virol 2013, 87(8):74-4461.
27. Lee D, Kim HZ, Jeong KW, Shim YS, Horikawa I, Barrett JC, Choe J. Human papillomavirus E2 down-regulates the human telomerase reverse transcriptase promoter. J Biol Chem 2002, 277(31):27748-56. 10.1074/jbc.M203706200, 12019268.
28. Lee DK, Kim BC, Kim IY, Cho EA, Satterwhite DJ, Kim SJ. The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding of the Smad complex to its target sequence. J Biol Chem 2002, 277(41):38557-64. 10.1074/jbc.M206786200, 12145312.
29. Ashrafi GH, Haghshenas M, Marchetti B, Campo MS. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 2006, 119:2105-2112. 10.1002/ijc.22089, 16823848.
30. Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K, Kojima S, Yasugi T, Kozuma S, Taketani Y. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol 2010, 84(22):11614-23. 10.1128/JVI.01053-10, 2977886, 20810727.
31. Oh JM, Kim SH, Lee YI, Seo M, Kim SY, Song YS, Kim WH, Juhnn YS. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 2009, 30(1):141-9.
32. Wang Q, Kennedy A, Das P, McIntosh PB, Howell SA, Isaacson ER, Hinz SA, Davy C, Doorbar J. Phosphorylation of the human papillomavirus type 16 E1-E4 protein at T57 by ERK triggers a structural change that enhances keratin binding and protein stability. J Virol 2009, 83(8):3668-83. 10.1128/JVI.02063-08, 2663250, 19211765.
33. Davy CE, Ayub M, Jackson DJ, Das P, McIntosh P, Doorbar J. HPV16 E1-E4 protein is phosphorylated by Cdk2/cyclin A and relocalizes this complex to the cytoplasm. Virology 2006, 349(1):230-44. 10.1016/j.virol.2006.02.024, 16540140.
34. Liao S, Deng D, Hu X, Wang W, Li L, Li W, Zhou J, Xu G, Meng L, Wang S, Ma D. HPV16/18 E5, a promising candidate for cervical cancer vaccines, affects SCPs, cell proliferation and cell cycle, and forms a potential network with E6 and E7. Int J Mol Med 2013, 31(1):120-8.
35. Nuovo GJ, Wu X, Volinia S, Yan F, di Leva G, Chin N, Nicol AF, Jiang J, Otterson G, Schmittgen TD, Croce C. Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. Diagn Mol Pathol 2010, 19(3):135-43. 10.1097/PDM.0b013e3181c4daaa, 20736742.
36. Bhattacharjya S, Nath S, Ghose J, Maiti GP, Biswas N, Bandyopadhyay S, Panda CK, Bhattacharyya NP, Roychoudhury S. miR-125b promotes cell death by targeting spindle assembly checkpoint gene MAD1 and modulating mitotic progression. Cell Death Differ 2013, 20(3):430-42. 10.1038/cdd.2012.135, 23099851.
37. McPhillips MG, Veerapraditsin T, Cumming SA, Karali D, Milligan SG, Boner W, Morgan IM, Graham SV. SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells. J Virol 2004, 78(19):10598-605. 10.1128/JVI.78.19.10598-10605.2004, 516382, 15367627.
38. Somberg M, Schwartz S. Multiple ASF/SF2 sites in the human papillomavirus type 16 (HPV-16) E4-coding region promote splicing to the most commonly used 3'-splice site on the HPV-16 genome. J Virol 2010, 84(16):8219-30. 10.1128/JVI.00462-10, 2916536, 20519389.
39. Rosenberger S, De-Castro Arce J, Langbein L, Steenbergen RD, Rösl F. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. Proc Natl Acad Sci USA 2010, 107(15):7006-11. 10.1073/pnas.1002620107, 2872467, 20351270.
40. Zhao X, Rush M, Schwartz S. Identification of an hnRNP A1-dependent splicing silencer in the human papillomavirus type 16 L1 coding region that prevents premature expression of the late L1 gene. J Virol 2004, 78(20):10888-905. 10.1128/JVI.78.20.10888-10905.2004, 521837, 15452209.
41. Kranjec C, Banks L. A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctions. J Virol 2011, 85(4):1757-64. 10.1128/JVI.01756-10, 3028909, 21123374.
42. Villota C, Campos A, Vidaurre S, Oliveira-Cruz L, Boccardo E, Burzio VA, Varas M, Villegas J, Villa LL, Valenzuela PD, Socías M, Roberts S, Burzio LO. Expression of mitochondrial non-coding RNAs (ncRNAs) is modulated by high risk human papillomavirus (HPV) oncogenes. J Biol Chem 2012, 287(25):21303-15. 10.1074/jbc.M111.326694, 3375551, 22539350.
43. Gao LJ, Gu PQ, Fan WM, Liu Z, Qiu F, Peng YZ, Guo XR. The role of gC1qR in regulating survival of human papillomavirus 16 oncogene-transfected cervical cancer cells. Int J Oncol 2011, 39(5):1265-72.
44. Nor Rashid N, Yusof R, Watson RJ. Disruption of repressive p130-DREAM complexes by human papillomavirus 16 E6/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells. J Gen Virol 2011, 92(Pt 11):2620-7.
45. Diaz-Chavez J, Hernandez-Pando R, Lambert PF, Gariglio P. Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer. Mol Cancer 2008, 7:3. 10.1186/1476-4598-7-3, 2248208, 18184435.
46. Liang F, Kina S, Takemoto H, Matayoshi A, Phonaphonh T, Sunagawa N, Arakaki K, Arasaki A, Kuang H, Sunakawa H. HPV16E6-dependent c-fos expression contributes to AP-1 complex formation in SiHa cells. Mediators Inflamm 2011, 2011:263216. 3147133, 21822357.
47. Peralta-Zaragoza O, Bermúdez-Morales V, Gutiérrez-Xicotencatl L, Alcocer-González J, Recillas-Targa F, Madrid-Marina V. E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor beta1 promoter throughout Sp1 recognition sequence. Viral Immunol 2006, 19(3):468-80. 10.1089/vim.2006.19.468, 16987065.
48. Xu Q, Wang S, Xi L, Wu S, Chen G, Zhao Y, Wu Y, Ma D. Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway. Gynecol Oncol 2006, 101(1):132-9. 10.1016/j.ygyno.2005.09.051, 16269171.
49. Dey A, Atcha IA, Bagchi S. HPV16 E6 oncoprotein stimulates the transforming growth factor-beta 1 promoter in fibroblasts through a specific GC-rich sequence. Virology 1997, 228(2):190-9. 10.1006/viro.1996.8363, 9123825.
50. Torng PL, Chan WY, Lin CT, Huang SC. Decreased expression of human papillomavirus E2 protein and transforming growth factor-beta1 in human cervical neoplasia as an early marker in carcinogenesis. J Surg Oncol 2003, 84(1):17-23. 10.1002/jso.10273, 12949986.
51. Deng W, Tsao SW, Kwok YK, Wong E, Huang XR, Liu S, Tsang CM, Ngan HY, Cheung AN, Lan HY, Guan XY, Cheung AL. Transforming growth factor beta1 promotes chromosomal instability in human papillomavirus 16 E6E7-infected cervical epithelial cells. Cancer Res 2008, 68(17):7200-9. 10.1158/0008-5472.CAN-07-6569, 18757436.
52. Tian Y, Wu P, Luo AY, Xi L, Zhou JF, Ma D. Expression and significance of Smad2/3 and HPV16 E7 in cervical intraepithelial neoplasia and cervical carcinoma. Ai Zheng 2007, 26(9):967-71.
53. Kloth JN, Kenter GG, Spijker HS, Uljee S, Corver WE, Jordanova ES, Fleuren GJ, Gorter A. Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod Pathol 2008, 21(7):866-75. 10.1038/modpathol.2008.62, 18425078.
54. Hariharan R, Babu JM PR, Pillai MR. Mutational analysis of Smad7 in human cervical cancer. Oncol Rep 2009, 21(4):1001-4.
55. Donalisio M, Cornaglia M, Landolfo S, Lembo D. TGF-beta1 and IL-4 downregulate human papillomavirus-16 oncogene expression but have differential effects on the malignant phenotype of cervical carcinoma cells. Virus Res 2008, 132(1-2):253-6.
56. Baldwin A, Pirisi L, Creek KE. NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression. J Virol 2004, 78(8):3953-3964. 10.1128/JVI.78.8.3953-3964.2004, 374275, 15047811.
57. Shier MK, Neely EB, Ward MG, Meyers C, Howett MK. Transforming growth factor beta 1 (TGF beta 1) down-regulates expression and function of proliferation-inducing molecules in HPV-transformed cells. Anticancer Res 1999, 19(6B):4977-82.
58. Shier MK, Neely EB, Ward MG, Richards ME, Manders EC, Meyers C, Howett MK. Correlation of TGF beta 1 overexpression with down-regulation of proliferation-inducing molecules in HPV-11 transformed human tissue xenografts. Anticancer Res 1999, 19(6B):4969-76.
59. Uren A, Fallen S, Yuan H, Usubütün A, Küçükali T, Schlegel R, Toretsky JA. Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res 2005, 65(14):6199-206. 10.1158/0008-5472.CAN-05-0455, 16024621.
60. Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, Psyrri A. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 2010, 8(3):433-43. 10.1158/1541-7786.MCR-09-0345, 20215420.
61. Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A. Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice. PLoS One 2011, 6(11):e27243. 10.1371/journal.pone.0027243, 3210148, 22087269.
62. van der Meide WF, Snellenberg S, Meijer CJ, Baalbergen A, Helmerhorst TJ, van der Sluis WB, Snijders PJ, Steenbergen RD. Promoter methylation analysis of WNT/β-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. Gynecol Oncol 2011, 123(1):116-22. 10.1016/j.ygyno.2011.06.015, 21726894.
63. Talora C, Cialfi S, Segatto O, Morrone S, Kim Choi J, Frati L, Paolo Dotto G, Gulino A, Screpanti I. Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res 2005, 305(2):343-54. 10.1016/j.yexcr.2005.01.015, 15817159.
64. Henken FE, De-Castro Arce J, Rösl F, Bosch L, Meijer CJ, Snijders PJ, Steenbergen RD. The functional role of Notch signaling in HPV-mediated transformation is dose-dependent and linked to AP-1 alterations. Cell Oncol (Dordr). 2012, 35(2):77-84. 10.1007/s13402-011-0062-4, 3306567, 22271085.
65. Veeraraghavalu K, Subbaiah VK, Srivastava S, Chakrabarti O, Syal R, Krishna S. Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation. J Virol 2005, 79(12):7889-98. 10.1128/JVI.79.12.7889-7898.2005, 1143639, 15919944.
66. Veeraraghavalu K, Pett M, Kumar RV, Nair P, Rangarajan A, Stanley MA, Krishna S. Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in JAGGED1 and manic fringe expression linked to notch activation. J Virol 2004, 78(16):8687-700. 10.1128/JVI.78.16.8687-8700.2004, 479091, 15280477.
67. Weijzen S, Zlobin A, Braid M, Miele L, Kast WM. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol 2003, 194(3):356-62. 10.1002/jcp.10217, 12548555.
68. Munagala R, Kausar H, Munjal C, Gupta RC. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 2011, 32(11):1697-705. 10.1093/carcin/bgr192, 21859835.
69. Zhang G, Liu Y, Yu L, Sun L. GFP/HPV-16E6 fusion protein induces apoptosis in MCF-7 and 293T cells using a transient expression system. Oncol Rep 2012, 28(5):1673-80.
70. Mahata S, Maru S, Shukla S, Pandey A, Mugesh G, Das BC, Bharti AC. Anticancer property of Bryophyllum pinnata (Lam.) Oken. leaf on human cervical cancer cells. BMC Complement Altern Med 2012, 12:15. 10.1186/1472-6882-12-15, 3353166, 22405256.
71. Preethy CP, Padmapriya R, Periasamy VS, Riyasdeen A, Srinag S, Krishnamurthy H, Alshatwi AA, Akbarsha MA. Antiproliferative property of n-hexane and chloroform extracts of Anisomeles malabarica (L). R. Br. in HPV16-positive human cervical cancer cells. J Pharmacol Pharmacother. 2012, 3(1):26-34. 10.4103/0976-500X.92500, 3284032, 22368413.
72. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012, 11(1):3-13.
73. Fulda S. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. Exp Cell Res 2012, 318(11):1208-12. 10.1016/j.yexcr.2012.02.005, 22366288.
74. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, Roden RB. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009, 15(2):570-7. 10.1158/1078-0432.CCR-08-1813, 2714480, 19147762.
75. Darvas K, Rosenberger S, Brenner D, Fritsch C, Gmelin N, Krammer PH, Rösl F. Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int J Cancer 2010, 127(6):1384-92. 10.1002/ijc.25170, 20087862.
76. Eaton S, Wiktor P, Thirstrup D, Lake D, Nagaraj VJ. Efficacy of TRAIL treatment against HPV16 infected cervical cancer cells undergoing senescence following siRNA knockdown of E6/E7 genes. Biochem Biophys Res Commun 2011, 405(1):1-6. 10.1016/j.bbrc.2010.12.056, 21167816.
77. Reiser J, Hurst J, Voges M, Krauss P, Münch P, Iftner T, Stubenrauch F. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 2011, 85(21):11372-80. 10.1128/JVI.05279-11, 3194958, 21849431.
78. Martinez-Velazquez M, Melendez-Zajgla J, Maldonado V. Apoptosis induced by cAMP requires Smac/DIABLO transcriptional upregulation. Cell Signal 2007, 19(6):1212-20. 10.1016/j.cellsig.2007.01.001, 17320350.
79. Xie W, Jiang P, Miao L, Zhao Y, Zhimin Z, Qing L, Zhu WG, Wu M. Novel link between E2F1 and Smac/DIABLO: proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1. Nucleic Acids Res 2006, 34(7):2046-55. 10.1093/nar/gkl150, 1440883, 16617145.
80. Wang F, Li Y, Zhou J, Xu J, Peng C, Ye F, Shen Y, Lu W, Wan X, Xie X. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011, 179(5):2580-8. 10.1016/j.ajpath.2011.07.037, 3204087, 21945323.
81. Wang W, Fang Y, Sima N, Li Y, Li W, Li L, Han L, Liao S, Han Z, Gao Q, Li K, Deng D, Meng L, Zhou J, Wang S, Ma D. Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell lines is mediated by interaction with c-FLIP. Apoptosis 2011, 16(1):55-66. 10.1007/s10495-010-0543-3, 20882347.
82. Wang W, Xia X, Wang S, Sima N, Li Y, Han Z, Gao Q, Luo A, Li K, Meng L, Zhou J, Wang C, Shen K, Ma D. Oncolytic adenovirus armed with human papillomavirus E2 gene in combination with radiation demonstrates synergistic enhancements of antitumor efficacy. Cancer Gene Ther 2011, 18(11):825-36. 10.1038/cgt.2011.53, 21852812.
83. Wang X, Meyers C, Guo M, Zheng ZM. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int J Cancer 2011, 129(6):1362-72. 10.1002/ijc.25800, 3086996, 21128241.
84. Vogt M, Butz K, Dymalla S, Semzow J, Hoppe-Seyler F. Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene 2006, 25(29):4009-15. Epub 2006 Feb 6, 10.1038/sj.onc.1209429, 16462759.
85. Khan S, Chib R, Shah BA, Wani ZA, Dhar N, Mondhe DM, Lattoo S, Jain SK, Taneja SC, Singh JA. Cyano analogue of boswellic acid induces crosstalk between p53/PUMA/Bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. Eur J Pharmacol 2011, 660(2-3):241-8. Epub 2011 Apr 2, 10.1016/j.ejphar.2011.03.013, 21440536.
86. Guo C, Liu K, Zheng Y, Luo H, Chen H, Huang L. Apoptosis induced by an antagonist peptide against HPV16 E7 in vitro and in vivo via restoration of p53. Apoptosis 2011, 16(6):606-18. 10.1007/s10495-011-0594-0, 21475994.
87. Guo CP, Liu KW, Luo HB, Chen HB, Zheng Y, Sun SN, Zhang Q, Huang L. Potent Anti-Tumor Effect Generated by a Novel Human Papillomavirus (HPV) Antagonist Peptide Reactivating the pRb/E2F Pathway. PLoS One 2011, 6(3):e17734. 10.1371/journal.pone.0017734, 3057995, 21423621.
88. Zhao CY, Szekely L, Bao W, Selivanova G. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res 2010, 70(8):3372-81. 10.1158/0008-5472.CAN-09-2787, 20395210.
89. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004, 279(10):8627-34. 10.1074/jbc.M312866200, 14684737.
90. Tan S, Hougardy BM, Meersma GJ, Schaap B, de Vries EG, van der Zee AG, de Jong S. Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells. Mol Pharmacol 2012, 81(5):701-9. 10.1124/mol.111.076539, 22328720.
91. Guan B, Yue P, Clayman GL, Sun SY. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001, 188(1):98-105. 10.1002/jcp.1101, 11382926.
92. Kabsch K, Mossadegh N, Kohl A, Komposch G, Schenkel J, Alonso A, Tomakidi P. The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte raft cultures. Intervirology 2004, 47(1):48-56. 10.1159/000076642, 15044836.
93. Vannucchi S, Chiantore MV, Fiorucci G, Percario ZA, Leone S, Affabris E, Romeo G. TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells. Oncogene 2005, 24(15):2536-46. 10.1038/sj.onc.1208403, 15735750.
94. Garnett TO, Filippova M, Duerksen-Hughes PJ. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 2006, 13(11):1915-26. 10.1038/sj.cdd.4401886, 1601974, 16528386.
95. Saitoh T, Hirai M, Katoh M. Molecular cloning and characterization of human Frizzled-8 gene on chromosome 10p11.2. Int J Oncol 2001, 18(5):991-6.
96. Yin S, Xu L, Bonfil RD, Banerjee S, Sarkar FH, Sethi S, Reddy KB. Tumor Initiating Cells and FZD8 play a major role in drug resistance in Triple- Negative Breast Cancer. Mol Cancer Ther 2013, 12(4):8-491.
97. He F, Wang Q, Zheng XL, Yan JQ, Yang L, Sun H, Hu LN, Lin Y, Wang X. Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species. Oncol Rep 2012, 28(2):601-5.
98. Bruning A, Vogel M, Mylonas I, Friese K, Burges A. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets 2011, 11(7):799-809. 10.2174/156800911796798913, 21762082.
99. Im SR, Jang YJ. Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1/2 activation in human cervical cancer cells. Biochem Biophys Res Commun 2012, 424(1):65-70. 10.1016/j.bbrc.2012.06.067, 22728039.
100. Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer 2012, 11:84. 10.1186/1476-4598-11-84, 3526430, 23158473.
101. Thanaketpaisarn O, Waiwut P, Sakurai H, Saiki I. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways. Int J Oncol 2011, 39(1):279-85.
102. Hougardy BM, Reesink-Peters N, van den Heuvel FA, ten Hoor KA, Hollema H, de Vries EG, de Jong S, van der Zee AG. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int J Cancer 2008, 123(6):1457-65. 10.1002/ijc.23684, 18567003.
103. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Sakai T. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem Biophys Res Commun 2005, 333(3):833-8. 10.1016/j.bbrc.2005.05.179, 15963948.
104. Huong le D, Shim JH, Choi KH, Shin JA, Choi ES, Kim HS, Lee SJ, Kim SJ, Cho NP, Cho SD. Effect of β-phenylethyl isothiocyanate from cruciferous vegetables on growth inhibition and apoptosis of cervical cancer cells through the induction of death receptors 4 and 5. J Agric Food Chem 2011, 59(15):8124-31. 10.1021/jf2006358, 21702500.
105. Eum DY, Byun JY, Yoon CH, Seo WD, Park KH, Lee JH, Chung HY, An S, Suh Y, Kim MJ, Lee SJ. Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction. Anticancer Drugs 2011, 22(8):763-73. 10.1097/CAD.0b013e328347181a, 21642840.
106. Kendrick JE, Straughn JM, Oliver PG, Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD, Buchsbaum DJ. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol 2008, 108(3):591-7. 10.1016/j.ygyno.2007.11.039, 18177927.
107. Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Int J Radiat Oncol Biol Phys 2008, 72(2):543-52. 10.1016/j.ijrobp.2008.06.1902, 18793956.
108. Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, de Jong S. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer 2006, 118(8):1892-900. 10.1002/ijc.21580, 16287099.
109. VanOosten RL, Moore JM, Karacay B, Griffith TS. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol Ther 2005, 4(10):1104-12. 10.4161/cbt.4.10.2022, 16096370.
110. Lin T, Ding Z, Li N, Xu J, Luo G, Liu J, Shen J. 2-Tellurium-bridged β-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression. Carcinogenesis 2011, 32(2):154-67. 10.1093/carcin/bgq234, 21081474.
111. Xu J, Zhou JY, Wei WZ, Philipsen S, Wu GS. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 2008, 68(16):6718-26. 10.1158/0008-5472.CAN-08-0657, 2631399, 18701496.
112. Moon DO, Kim MO, Choi YH, Kim GY. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Mol Cancer Ther 2010, 9(6):1583-95. 10.1158/1535-7163.MCT-09-0942, 20515942.
113. Soncini M, Santoro F, Gutierrez A, Frigè G, Romanenghi M, Botrugno OA, Pallavicini I, Pelicci P, Di Croce L, Minucci S. The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. Biochim Biophys Acta 2013, 1832(1):114-20. 10.1016/j.bbadis.2012.10.001, 23046813.
114. Benoit YD, Laursen KB, Witherspoon MS, Lipkin SM, Gudas LJ. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. J Cell Physiol 2013, 228(4):764-72. 10.1002/jcp.24224, 23001792.
115. Laurson J, Khan S, Chung R, Cross K, Raj K. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 2010, 31(5):918-26. 10.1093/carcin/bgq027, 2864410, 20123756.
116. D'Costa ZJ, Jolly C, Androphy EJ, Mercer A, Matthews CM, Hibma MH. Transcriptional repression of E-cadherin by human papillomavirus type 16 E6. PLoS One 2012, 7(11):e48954. 10.1371/journal.pone.0048954, 3506579, 23189137.
117. Yadav VR, Prasad S, Aggarwal BB. Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins. Br J Pharmacol 2012, 165(3):741-53. 10.1111/j.1476-5381.2011.01603.x, 3315045, 21797841.
118. Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis 2008, 13(6):756-70. 10.1007/s10495-008-0210-0, 18421578.
119. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004, 64(15):5078-83. 10.1158/0008-5472.CAN-04-1195, 15289308.
120. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G, Paul JT, Gibson SB. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005, 25(13):5404-16. 10.1128/MCB.25.13.5404-5416.2005, 1156987, 15964798.
121. Ramesh E, Alshatwi AA. Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food Chem Toxicol 2013, 51:97-105.
122. Kim H, Jeong D, Kang HE, Lee KC. Na KA sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres. J Pharm Pharmacol 2013, 65(1):11-21. 10.1111/j.2042-7158.2012.01564.x, 23215683.
123. Zheng Y, Chen H, Zeng X, Liu Z, Xiao X, Zhu Y, Gu D, Mei L. Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy. Nanoscale Res Lett 2013, 8(1):161. 10.1186/1556-276X-8-161, 3639870, 23570619.
124. Lirdprapamongkol K, Sakurai H, Abdelhamed S, Yokoyama S, Athikomkulchai S, Viriyaroj A, Awale S, Ruchirawat S, Svasti J, Saiki I. Chrysin overcomes TRAIL resistance of cancer cells through Mcl-1 downregulation by inhibiting STAT3 phosphorylation. Int J Oncol 2013,
125. Zhang Z, Ye T, Cai X, Yang J, Lu W, Hu C, Wang Z, Wang X, Cao P. 5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins. Evid Based Complement Alternat Med. 2013, 2013:434709. 3600283, 23533482.
126. Kim EY, Kim AK. Combination effect of equol and TRAIL against human cervical cancer cells. Anticancer Res 2013, 33(3):903-12.
127. Bodaghi S, Jia R, Zheng ZM. Human papillomavirus type 16 E2 and E6 are RNA-binding proteins and inhibit in vitro splicing of pre-mRNAs with suboptimal splice sites. Virology 2009, 386(1):32-43. 10.1016/j.virol.2008.12.037, 2683163, 19187948.
128. Song JJ, Szczepanski MJ, Kim SY, Kim JH, An JY, Kwon YT, Alcala MA, Bartlett DL, Lee YJ. c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal 2010, 22(3):553-63. 10.1016/j.cellsig.2009.11.012, 2973327, 19932172.
129. Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, Jin J, Harper JW, Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 2007, 81(18):9737-47. 10.1128/JVI.00881-07, 2045412, 17609271.
130. van de Kooij B, Verbrugge I, de Vries E, Gijsen M, Montserrat V, Maas C, Neefjes J, Borst J. Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of the death receptor TRAIL-R1. J Biol Chem 2013, 2889(9):28-6617.
131. Shi M, Du L, Liu D, Qian L, Hu M, Yu M, Yang Z, Zhao M, Chen C, Guo L, Wang L, Song L, Ma Y, Guo N. Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 2012, 228(2):148-57. 10.1002/path.3997, 22287315.
132. Au Yeung CL, Tsang TY, Yau PL, Kwok TT. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 2011, 30(21):2401-2410. 10.1038/onc.2010.613, 21242962.
133. Lajer CB, Garnæs E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D, Skotte L, Specht L, Buchwald C, Nielsen FC. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 2012, 106(9):1526-34. 10.1038/bjc.2012.109, 3341860, 22472886.
134. Botezatu A, Goia-Rusanu CD, Iancu IV, Huica I, Plesa A, Socolov D, Ungureanu C, Anton G. Quantitative analysis of the relationship between microRNA-124a, -34b and -203 gene methylation and cervical oncogenesis. Mol Med Report. 2011, 4(1):121-8.
135. Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ, Steenbergen RD. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 2010, 9:167. 2917428, 20579385.
136. Li Y, Liu J, Yuan C, Cui B, Zou X, Qiao Y. High-risk human papillomavirus reduces the expression of microRNA-218 in women with cervical intraepithelial neoplasia. J Int Med Res 2010, 38(5):1730-6. 10.1177/147323001003800518, 21309487.
137. Cui F, Li X, Zhu X, Huang L, Huang Y, Mao C, Yan Q, Zhu J, Zhao W, Shi H. MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta. Cell Physiol Biochem 2012, 30(5):1310-1318. 10.1159/000343320, 23160634.
138. Bao Y, Lin C, Ren J, Liu J. MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3K p110δ). Apoptosis 2013,
139. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012, 55(6):1852-62. 10.1002/hep.25576, 22234835.
140. Wei Q, Li YX, Liu M, Li X, Tang H. MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells. IUBMB Life 2012, 64(8):697-704. 10.1002/iub.1051, 22730212.
141. Liu J, Yang L, Zhang J, Zhang J, Chen Y, Li K, Li Y, Li Y, Yao L, Guo G. Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. BMC Cancer 2012, 12:370. 10.1186/1471-2407-12-370, 3493279, 22920753.
142. Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, Huang C, Zhou F, Liu M, Wu X, Wang X. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med. Report 2012, 5(3):753-60.
143. Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, Xie X, Zhou C, Lu W. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 2012,
144. Xu XM, Wang XB, Chen MM, Liu T, Li YX, Jia WH, Liu M, Li X, Tang H. MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett 2012, 322(2):148-58. 10.1016/j.canlet.2012.02.038, 22561557.
145. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. J Biol Chem 2012, 287(17):14301-9. 10.1074/jbc.M111.337642, 3340176, 22399294.
146. Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q, Li YX, Liu M, Li X, Tang H. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J Biol Chem 2011, 286(29):25556-63. 10.1074/jbc.M111.221564, 3138314, 21646351.
147. Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M, Zhu Y, Zhao Q, Dong YW, Shao K, Wu A, Wu XZ. MicroRNA-223 regulates FOXO1 expression and cell proliferation. FEBS Lett 2012, 586(7):1038-43. 10.1016/j.febslet.2012.02.050, 22569260.
148. Bierkens M, Krijgsman O, Wilting SM, Bosch L, Jaspers A, Meijer GA, Meijer CJ, Snijders PJ, Ylstra B, Steenbergen RD. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer 2013, 52(1):56-68. 10.1002/gcc.22006, 22987659.
149. López JA, Alvarez-Salas LM. Differential effects of miR-34c-3p and miR-34c-5p on SiHa cells proliferation apoptosis, migration and invasion. Biochem Biophys Res Commun 2011, 409(3):513-9. 10.1016/j.bbrc.2011.05.036, 21600876.
150. Melar-New M, Laimins LA. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol 2010, 84(10):5212-21. 10.1128/JVI.00078-10, 2863797, 20219920.
151. Greco D, Kivi N, Qian K, Leivonen SK, Auvinen P, Auvinen E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One 2011, 6(7):e21646. 10.1371/journal.pone.0021646, 3128596, 21747943.
152. Luo M, Shen D, Zhou X, Chen X, Wang W. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery 2013, 153(6):47-836.
153. Li S, Li Y, Hu R, Li W, Qiu H, Cai H, Wang S. The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells. Oncol Lett 2013, 5(2):717-721. 3573114, 23420667.
154. Long MJ, Wu FX, Li P, Liu M, Li X, Tang H. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett 2012, 324(2):186-96. 10.1016/j.canlet.2012.05.022, 22634495.
155. Xie H, Zhao Y, Caramuta S, Larsson C, Lui WO. miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One 2012, 7(10):e46990. 10.1371/journal.pone.0046990, 3463520, 23056551.
156. Qin W, Dong P, Ma C, Mitchelson K, Deng T, Zhang L, Sun Y, Feng X, Ding Y, Lu X, He J, Wen H, Cheng J. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene 2012, 31(36):4067-75. 10.1038/onc.2011.561, 22179829.
157. Kang HW, Wang F, Wei Q, Zhao YF, Liu M, Li X, Tang H. miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett 2012, 586(6):897-904. 10.1016/j.febslet.2012.02.020, 22449978.
158. Li JH, Xiao X, Zhang YN, Wang YM, Feng LM, Wu YM, Zhang YX. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol 2011, 120(1):145-51. 10.1016/j.ygyno.2010.09.009, 20947150.
159. Myklebust MP, Bruland O, Fluge T, Skarstein A, Balteskard L, Dahl O. MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. Br J Cancer 2011, 105(11):1719-25. 10.1038/bjc.2011.457, 3242611, 22045185.
160. Shi TY, Chen XJ, Zhu ML, Wang MY, He J, Yu KD, Shao ZM, Sun MH, Zhou XY, Cheng X, Wu X, Wei Q. A pri-miR-218 variant and risk of cervical carcinoma in Chinese women. BMC Cancer 2013, 13(1):19. 10.1186/1471-2407-13-19, 3585813, 23320911.
161. Wilting SM, Verlaat W, Jaspers A, Makazaji NA, Agami R, Meijer CJ, Snijders PJ, Steenbergen RD. Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics 2013, 16:8(2).
162. Tang T, Wong HK, Gu W, Yu MY, To KF, Wang CC, Wong YF, Cheung TH, Chung TK, Choy KW. MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol 2013, 129(1):199-208. 10.1016/j.ygyno.2012.12.043, 23313739.
163. Druz A, Chen YC, Guha R, Betenbaugh M, Martin SE, Shiloach J. Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines. RNA Biol 2013, 25:10(2).
164. Wang F, Liu M, Li X, Tang H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett 2013, S0014-5793(13)00047-1:S0014-5793(13)00047-1. S0014-5793(13)00047-1.
165. Feng L, Xie Y, Zhang H, Wu Y. Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650. Biochem Biophys Res Commun 2011, 406(4):534-8. 10.1016/j.bbrc.2011.02.081, 21352815.
166. Wen X, Li D, Zhang Y, Liu S, Ghali L, Iles RK. Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations. Anticancer Drugs 2012, 23(3):280-7. 10.1097/CAD.0b013e32834f1fd3, 22245994.
167. Yang J, Li S, Guo F, Zhang W, Wang Y, Pan Y. Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes in cervical cancer cells. Mol Med Report. 2012,
168. Zhou J, Peng C, Li B, Wang F, Zhou C, Hong D, Ye F, Cheng X, Lü W, Xie X. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecol Oncol 2012, 124(2):296-302. 10.1016/j.ygyno.2011.10.028, 22056554.
169. Riyasdeen A, Periasamy VS, Paul P, Alshatwi AA, Akbarsha MA. Chloroform Extract of Rasagenthi Mezhugu, a Siddha Formulation, as an Evidence-Based Complementary and Alternative Medicine for HPV-Positive Cervical Cancers. Evid Based Complement Alternat Med. 2012, 2012:136527. 3205714, 22114617.
170. Tseng CW, Monie A, Trimble C, Alvarez RD, Huh WK, Buchsbaum DJ, Straughn JM, Wang MC, Yagita H, Hung CF, Wu TC. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008, 26(34):4314-9. 10.1016/j.vaccine.2008.06.049, 2614388, 18598733.
171. Le Poole IC, ElMasri WM, Denman CJ, Kroll TM, Bommiasamy H, Lyons Eiben G, Kast WM. Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother 2008, 57(6):789-97. 10.1007/s00262-007-0415-z, 18004565.
172. Alshatwi AA, Ramesh E, Periasamy VS, Subash-Babu P. The apoptotic effect of hesperetin on human cervical cancer cells is mediated through cell cycle arrest, death receptor, and mitochondrial pathways. Fundam Clin Pharmacol 2012,
173. Lee S, Kim H, Kang JW, Kim JH, Lee DH, Kim MS, Yang Y, Woo ER, Kim YM, Hong J, Yoon DY. The biflavonoid amentoflavone induces apoptosis via suppressing E7 expression, cell cycle arrest at sub-G1 phase, and mitochondria-emanated intrinsic pathways in human cervical cancer cells. J Med Food 2011, 14(7-8):808-16. 10.1089/jmf.2010.1428, 21663495.
174. Maher DM, Bell MC, O'Donnell EA, Gupta BK, Jaggi M, Chauhan SC. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog 2011, 50(1):47-57. 10.1002/mc.20695, 21061268.
175. Reschner A, Bontems S, Le Gac S, Lambermont J, Marcélis L, Defrancq E, Hubert P, Moucheron C, Kirsch-De Mesmaeker A, Raes M, Piette J, Delvenne P. Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53. Gene Ther 2012, 10.1038/gt.2012.54.
176. Togtema M, Pichardo S, Jackson R, Lambert PF, Curiel L, Zehbe I. Sonoporation delivery of monoclonal antibodies against human papillomavirus 16 E6 restores p53 expression in transformed cervical keratinocytes. PLoS One 2012, 7(11):e50730. 10.1371/journal.pone.0050730, 3511358, 23226365.
177. Zhou Y, Wei Y, Zhu J, Wang Q, Bao L, Ma Y, Chen Y, Feng D, Zhang A, Sun J, Nallar SC, Shen K, Kalvakolanu DV, Xiao W, Ling B. GRIM-19 disrupts E6/E6AP complex to rescue p53 and induce apoptosis in cervical cancers. PLoS One 2011, 6(7):e22065. 10.1371/journal.pone.0022065, 3134474, 21765936.
178. Yew CW, Lee P, Chan WK, Lim VK, Tay SK, Tan TM, Deng LW. A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers. Cancer Res 2011, 71(21):6696-707. 10.1158/0008-5472.CAN-11-1271, 21908553.
179. Ye Y, Xu W, Zhong W, Li Y, Wang C. Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation. Mol Cell Biochem 2012, 363(1-2):191-202.
180. Hernandez-Flores G, Ortiz-Lazareno PC, Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF, Aguilar-Lemarroy Adel C, de Celis-Carrillo R, del Toro-Arreola S, Castellanos-Esparza YC, Bravo-Cuellar A. Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. BMC Cancer 2011, 11:483. 10.1186/1471-2407-11-483, 3229613, 22074157.
181. Ocadiz-Delgado R, Castañeda-Saucedo E, Indra AK, Hernandez-Pando R, Flores-Guizar P, Cruz-Colin JL, Recillas-Targa F, Perez-Ishiwara G, Covarrubias L, Gariglio P. RXRα deletion and E6E7 oncogene expression are sufficient to induce cervical malignant lesions in vivo. Cancer Lett 2012, 317(2):226-36. 10.1016/j.canlet.2011.11.031, 22138104.
182. Phuah NH, In LL, Azmi MN, Ibrahim H, Awang K, Nagoor NH. Alterations of MicroRNA Expression Patterns in Human Cervical Carcinoma Cells (Ca Ski) toward 1'S-1'-Acetoxychavicol Acetate and Cisplatin. Reprod Sci 2013, 20(5):78-567.
183. Samarzija I, Beard P. Hedgehog pathway regulators influence cervical cancer cell proliferation, survival and migration. Biochem Biophys Res Commun 2012, 425(1):64-9. 10.1016/j.bbrc.2012.07.051, 22820185.
184. Mason TA, Kolobova E, Liu J, Roland JT, Chiang C, Goldenring JR. Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signaling. PLoS One 2011, 6(11):e27699. 10.1371/journal.pone.0027699, 3216988, 22110729.
185. Zhao Y, Li Y, Wang L, Yang H, Wang Q, Qi H, Li S, Zhou P, Liang P, Wang Q, Li X. microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer. J Exp Clin Cancer Res 2013, 32(1):10. 10.1186/1756-9966-32-10, 23442927.
186. Bo Y, Guo G, Yao W. miRNA-mediated tumor specific delivery of TRAIL reduced glioma growth. J Neurooncol 2013, 112(1):27-37. 10.1007/s11060-012-1033-y, 23338605.